NASDAQ:AYTU

Aytu BioPharma Q1 2027 Earnings Results & Report

Aytu BioPharma logo
$2.66 0.00 (0.00%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$2.66 -0.01 (-0.19%)
As of 11/20/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aytu BioPharma beat analyst expectations on both earnings and revenue in its Q1 2027 results, released November 16, 2026. The company reported EPS of -$0.20 versus the -$0.2567 consensus estimate, while revenue of $14.84 million topped the $13.27 million estimate by $1.57 million.

Earnings Announcement Details

Quarter
Q1 2027
Time
After Market Closes
Conference Call
4:30 PM ET

Aytu BioPharma EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.2567
Beat/Miss
Beat by +$0.0567
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Aytu BioPharma Revenue Results

Actual Revenue
$14.84 million
Expected Revenue
$13.27 million
Beat/Miss
Beat by +$1.57 million
YoY Revenue Growth
N/A

Upcoming Earnings

Aytu BioPharma's Q2 2027 earnings is estimated for Tuesday, February 2, 2027, based on past reporting schedules, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Aytu BioPharma Q1 2027 Earnings FAQ

Aytu BioPharma (NASDAQ:AYTU) reported earnings of -$0.20 per share for Q1 2027, beating the consensus estimate of -$0.2567. The report was announced on Monday, November 16, 2026.

Aytu BioPharma reported revenue of $14.84 million for Q1 2027, against a consensus estimate of $13.27 million.

Aytu BioPharma's next earnings date is estimated for Tuesday, February 2, 2027. MarketBeat tracks confirmed and estimated earnings dates for Aytu BioPharma on the company's earnings history page.

Aytu BioPharma Earnings Headlines

Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Aytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Maxim Group
Aytu BioPharma (NASDAQ:AYTU) Stock Rating Lowered by Lake Street Capital
See More Aytu BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aytu BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aytu BioPharma and other key companies, straight to your email.

About Aytu BioPharma

Aytu BioPharma (NASDAQ:AYTU), Inc. is a specialty pharmaceutical company focused on developing and commercializing prescription treatments. Its business has centered on medicines for attention-deficit/hyperactivity disorder (ADHD) and other pediatric conditions.

The company’s product portfolio has included ADHD medications such as Adzenys XR-ODT, an orally disintegrating amphetamine tablet, and Cotempla XR-ODT, an extended-release methylphenidate tablet. Aytu has also marketed treatments for other pediatric needs, including allergies.

Aytu’s commercial activities have primarily served the U.S. market. The company has grown through acquisitions, including the 2021 acquisition of Neos Therapeutics, which added ADHD products to its portfolio.

View Aytu BioPharma Profile